NIS495.1m market cap
NIS14.9 last close
Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson’s in Phase III and AP-ZP for insomnia in Phase II.
Investment summary
Edison Investment Research is terminating coverage on Intec Pharma (NTEC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 0.0 | (14.5) | (13.4) | (116.72) | N/A | N/A |
| 2017A | 0.0 | (30.1) | (29.1) | (164.74) | N/A | N/A |
| 2018E | 0.0 | (31.2) | (29.5) | (93.22) | N/A | N/A |
| 2019E | 0.0 | (25.0) | (22.8) | (67.94) | N/A | N/A |
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 57.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| John W Kozarich | Chairman |
| Jeffrey A Meckler | CEO |
| Nir Sassi | CFO |
